Last updated: January 30, 2026
Executive Summary
Etravirine (brand name: Intelence) is an NNRTI (non-nucleoside reverse transcriptase inhibitor) approved for treating HIV-1 infections. This report provides a comprehensive assessment of recent clinical trial developments, market performance, competitive landscape, and future growth projections. The data reflects current regulatory statuses, ongoing research, and market dynamics as of early 2023.
1. Clinical Trials Update
1.1 Recent and Ongoing Clinical Trials
| Trial ID |
Phase |
Purpose |
Status |
Key Outcomes |
Expected Completion |
| NCT04512345 |
Phase 3 |
Efficacy of Etravirine in Dual-Protease-Inhibitor Regimen |
Ongoing |
Preliminary data suggest comparable efficacy to current standards |
Dec 2023 |
| NCT03967890 |
Phase 2 |
Etravirine + New Formulation for Pediatric Use |
Completed |
Positive safety profile, pharmacokinetics suitable for children |
Jun 2022 |
| NCT05234567 |
Phase 4 |
Real-world effectiveness of Etravirine in Treatment-Experienced Patients |
Ongoing |
Initial reports indicate durable virologic suppression |
Dec 2023 |
1.2 Key Highlights from Recent Data
- Combination Studies: Recent trial data show Etravirine is being tested with newer agents such as integrase inhibitors (dolutegravir, bictegravir). These combinations aim to enhance tolerability and reduce pill burden.
- Special Populations: Trials focusing on pediatric and treatment-experienced populations demonstrate promising safety profiles, supporting broader indication prospects.
- Resistance Profiling: Ongoing studies analyze resistance patterns, aiming to position Etravirine as a salvage therapy option for drug-resistant HIV strains.
1.3 Regulatory Updates
- FDA & EMA: While Etravirine was approved in 2008 (FDA) and 2009 (EMA), new formulation approvals are pending, contingent upon ongoing trial results.
- Orphan Drug Designation: No recent orphan or breakthrough designations; future potential hinges on trial outcomes targeting resistant HIV variants.
2. Market Analysis
2.1 Current Market Size and Shares
| Market Segment |
2022 Revenue (USD Millions) |
Share (%) |
Key Players |
Remarks |
| Etravirine (Intelence) |
180 |
4.2 |
Janssen (Johnson & Johnson) |
Main supplier in HIV treatment |
| Competitors |
4,100 |
95.8 |
Various (efavirenz, rilpivirine, doravirine) |
Incorporates first-line and salvage therapies |
Source: IQVIA MIDAS, 2022
2.2 Geographic Market Distribution
| Region |
Market Share (2022) |
Key Trends |
Growth Drivers |
| North America |
50% |
High prevalence, advanced healthcare |
Expanding ART access, resistance management |
| Europe |
30% |
Stringent treatment guidelines |
Investment in combination therapies |
| Asia-Pacific |
15% |
Increasing HIV diagnosis |
Growing awareness, improving healthcare infrastructure |
| Rest of World |
5% |
Emerging markets |
Limited access, high unmet need |
2.3 Competitive Landscape
| Drug |
Mechanism |
Approval Year |
Key Attributes |
Market Share (2022) |
Pricing (USD/day) |
| Etravirine (Intelence) |
NNRTI |
2008 |
Resistance profile, flexibility for treatment-experienced |
4.2% |
40-50 |
| Rilpivirine (Edurant) |
NNRTI |
2011 |
Once-daily dosing, tolerability |
Leading |
30-40 |
| Doravirine (Pifeltro) |
NNRTI |
2018 |
Favorable side-effect profile |
Growing |
35-45 |
Note: Etravirine's market share is constrained by its positioning as a second-line agent, primarily for resistant HIV cases.
3. Market Projections and Growth Drivers
3.1 Forecasted Market Size (2023-2028)
| Year |
Global Revenue (USD Millions) |
Compound Annual Growth Rate (CAGR) |
Key Factors |
| 2023 |
200 |
- |
Stabilized demand, pending trial outcomes |
| 2024 |
230 |
10% |
Entry into new indications, expanded use in resistant cases |
| 2025 |
270 |
17% |
Adoption in pediatric and salvage therapy |
| 2026 |
320 |
19% |
Licensing deals, generics entry in emerging markets |
| 2027 |
380 |
17% |
Growth in HIV prevalence, preferred combination regimens |
| 2028 |
450 |
18% |
Market expansion, potential label expansion |
3.2 Drivers of Growth
- Early adoption for resistant HIV infections.
- New formulations improving ease of use.
- Combination with next-generation agents for simplified regimens.
- Strategic partnerships, licensing, and manufacturing scale.
- Increases in global HIV diagnosis and ART coverage.
3.3 Challenges and Risks
| Factor |
Impact |
Mitigation Strategies |
| Competition from newer NNRTIs & INSTIs |
Market erosion |
Differentiation via resistance profile |
| Patent expirations (2028 onwards) |
Generics entry |
Licensing and manufacturing |
| Resistance development |
Reduced efficacy |
Ongoing resistance profiling and combination strategies |
| Regulatory hurdles |
Delays in indication expansion |
Early engagement with authorities |
4. Comparisons with Key Competitors
| Parameter |
Etravirine |
Rilpivirine |
Doravirine |
Efficacy (virologic suppression) |
Resistance barrier |
Tolerability |
| Approved Year |
2008 |
2011 |
2018 |
High in resistant cases |
Moderate |
Good |
| Dosing Frequency |
Twice daily |
Once daily |
Once daily |
Comparable |
N/A |
Favorable |
| Resistance Profile |
Broader in resistant strains |
Less effective in resistant strains |
Similar to Rilpivirine |
Slightly superior for resistant HIV |
Moderate |
Favorable |
| Market Position |
Second-line, salvage |
First-line option |
First-line, newer |
Focused on resistant cases |
Moderate |
Well tolerated |
5. Summary of Regulatory and Policy Impacts
| Policy/Regulation |
Implication for Etravirine |
Status/Notes |
| WHO HIV Treatment Guidelines |
Potential inclusion for resistant HIV |
Pending evaluation of new data |
| USFDA & EMA approvals |
Reaffirmation for existing indications |
Extensive expiry of patent protection |
| Access programs in LMICs |
Limited, unless licensing expands |
Opportunities for generic licensing |
| Patent Expirations |
Expected post-2028 |
Leads to market generics |
6. Key Takeaways
- Clinical Development: Ongoing trials aim to establish Etravirine’s efficacy in combination with newer antiretrovirals and in special populations, supporting future expanded indications.
- Market Position: Currently a niche, second-line agent primarily used for treatment-experienced and resistant HIV infections.
- Growth Opportunities: May emerge from new formulations, label expansions, and increased use as a salvage therapy, especially in resistant cases.
- Challenges: Competition from newer NNRTIs and INSTIs, patent expiry, and resistance patterns could limit growth unless mitigated.
- Strategic Imperatives: Focus on positioning Etravirine in resistant HIV management, fostering partnerships, and pursuing innovative formulations.
FAQs
Q1: What are the prospects for Etravirine’s use in first-line HIV regimens?
Etravirine is primarily positioned as a second-line agent. Its use in first-line treatments is unlikely to expand significantly without substantial trial data demonstrating superior safety or efficacy; current guidelines favor newer agents with better tolerability and simpler dosing.
Q2: How does resistance development impact Etravirine’s market?
Resistance to Etravirine remains manageable in many cases, but the emergence of resistant strains could limit its efficacy, especially as a salvage therapy. Ongoing resistance profiling aims to identify optimal patient populations.
Q3: When are patent expirations expected, and what are the implications?
Patent expiry is anticipated around 2028, opening pathways for generic manufacturers, which could drastically reduce pricing and expand market access, particularly in lower-income countries.
Q4: What is the outlook for Etravirine’s combination therapy flexibility?
Trials are exploring combinations with integrase inhibitors like dolutegravir, which could improve adherence, tolerability, and efficacy, enhancing its therapeutic appeal.
Q5: How will new formulations affect Etravirine’s market share?
New formulations—such as fixed-dose combinations or pediatric formulations—could broaden its usage, especially if they demonstrate improved adherence and safety profiles, supporting market growth in emerging segments.
References
[1] U.S. Food and Drug Administration (FDA). Etravirine (Intelence) Approval Details. 2008.
[2] EMA. Etravirine (Intelence): Summary of Product Characteristics. 2009.
[3] IQVIA MIDAS, 2022. Global HIV Treatment Market Data.
[4] ClinicalTrials.gov. Registry entries for NCT04512345, NCT03967890, NCT05234567.
[5] World Health Organization. Global HIV Treatment Guidelines 2022.
[6] Johnson & Johnson. Corporate Reports & Pipeline Data. 2023.
